Anti-CCP Blood Test: Normal Ranges, Causes & What Your Results Mean

What Is Anti-CCP?

Anti-CCP (anti-cyclic citrullinated peptide) antibodies are autoantibodies - immune proteins that mistakenly target your own body's tissues rather than foreign invaders. Specifically, anti-CCP antibodies target proteins that have undergone a chemical modification called citrullination, in which the amino acid arginine is converted to citrulline.

Citrullination is a normal biological process that occurs during cell death, inflammation, and tissue remodelling. In most people, the immune system ignores citrullinated proteins. However, in individuals with a genetic predisposition, particularly those carrying certain HLA-DR4 gene variants, the immune system can misidentify these modified proteins as threats, producing anti-CCP antibodies that drive an inflammatory autoimmune response.

This autoimmune process is the central mechanism of rheumatoid arthritis (RA), and anti-CCP testing has become one of the most important tools in its early diagnosis. The antibodies can appear in the blood years, sometimes even a decade, before symptoms develop, making them a powerful early warning marker.

Why Is Anti-CCP Tested?

Anti-CCP testing is primarily used in the context of joint disease and autoimmune investigation:

• Diagnosing rheumatoid arthritis: Anti-CCP is the most specific blood test for RA, with a specificity of approximately 95–98%. This means that if anti-CCP is positive, there is a very high probability that the patient has or will develop RA.
• Differentiating RA from other forms of arthritis: Many conditions cause joint pain and swelling - osteoarthritis, psoriatic arthritis, gout, lupus-related arthritis. Anti-CCP helps distinguish RA from these mimics.
• Predicting disease course: Patients who are anti-CCP positive tend to develop more aggressive disease with greater joint erosion. This information helps rheumatologists make early decisions about treatment intensity.
• Confirming diagnosis when RF is negative: Rheumatoid factor (RF), the traditional antibody test for RA, is positive in only 70–80% of RA patients and can also be positive in many other conditions (infections, other autoimmune diseases, and even in healthy elderly individuals). Anti-CCP adds specificity that RF lacks.
• Early detection: Anti-CCP antibodies can be detected up to 10 years before the onset of clinical RA, enabling earlier intervention and better long-term outcomes.
• Monitoring risk in family members: First-degree relatives of RA patients who test positive for anti-CCP are at significantly increased risk of developing the disease.

Normal Anti-CCP Ranges

Anti-CCP is measured in units per millilitre (U/mL) using enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CLIA) methods. Results are typically reported as either positive or negative, with a quantitative value:

Result	Value (U/mL)	Interpretation
Negative	Less than 17 U/mL	Anti-CCP antibodies not detected. RA is unlikely but not excluded.
Weak positive	17–49 U/mL	Low-level positivity. May indicate early RA or need repeat testing.
Moderate positive	50–100 U/mL	Consistent with RA. Warrants rheumatology referral.
Strong positive	Greater than 100 U/mL	Strongly suggestive of RA. Associated with more aggressive disease.

Note that exact cut-off values vary between laboratories depending on the assay used. Always interpret your result in the context of the reference range provided by the testing laboratory.

Approximately 5% of healthy individuals may have a false positive anti-CCP result. Conversely, around 20–30% of patients with confirmed RA are anti-CCP negative (seronegative RA). A negative result does not definitively rule out RA if clinical suspicion is high.

What Do High Anti-CCP Levels Mean?

A positive anti-CCP result, particularly at moderate to high levels, strongly suggests rheumatoid arthritis. The higher the titre, the more likely the patient is to experience aggressive disease.

Conditions associated with positive anti-CCP

• Rheumatoid arthritis: The primary association. Approximately 70–80% of RA patients are anti-CCP positive. Positivity predicts erosive joint disease and poorer functional outcomes.
• Pre-clinical RA: Anti-CCP may be positive years before joint symptoms appear. This stage, sometimes called "at-risk RA", is an active area of research, with clinical trials investigating whether early treatment can prevent full-blown disease.
• Other autoimmune conditions (less commonly): Low-level anti-CCP positivity has been reported in systemic lupus erythematosus (2–5%), primary Sjogren's syndrome, psoriatic arthritis, and tuberculosis, though at much lower rates than in RA.
• Interstitial lung disease: Anti-CCP positive patients may develop lung fibrosis even in the absence of significant joint disease - a presentation known as anti-CCP positive interstitial lung disease.

What happens after a positive result

If your anti-CCP test is positive, your GP will typically refer you to a rheumatologist for further assessment. This may include:

• Physical examination of joints for swelling, tenderness, and warmth
• Additional blood tests: RF, ESR, CRP, full blood count
• Imaging: ultrasound or MRI of affected joints to detect early erosions and synovitis
• X-rays of hands and feet as a baseline

Early referral is critical. The NICE guidelines recommend that all patients with suspected RA are seen by a rheumatologist within 3 weeks of referral. Early treatment with disease-modifying anti-rheumatic drugs (DMARDs), typically methotrexate, can prevent irreversible joint damage.

What Does a Negative Anti-CCP Result Mean?

A negative anti-CCP result makes RA less likely but does not exclude it entirely. Seronegative RA accounts for 20–30% of all RA cases and can be just as debilitating as seropositive disease, though it tends to progress more slowly on average.

Other implications of a negative result include:

• Alternative diagnosis: Joint symptoms may be due to osteoarthritis, psoriatic arthritis, gout, reactive arthritis, or viral arthritis, none of which are associated with anti-CCP.
• Early disease: In very early RA, anti-CCP may not yet have reached detectable levels. If clinical suspicion remains, the test should be repeated after 3–6 months.
• Reassurance: In patients with non-specific joint pain and no other features of inflammatory arthritis, a negative anti-CCP is genuinely reassuring.

How to Manage Anti-CCP Positivity

Unlike many other biomarkers, you cannot directly lower your anti-CCP levels through lifestyle changes alone. However, there is strong evidence for strategies that reduce inflammation and may slow the progression from pre-clinical to established RA:

Lifestyle interventions

• Stop smoking: Smoking is the single strongest environmental risk factor for anti-CCP positive RA. It triggers citrullination in the lungs and amplifies the autoimmune response. Quitting smoking reduces risk significantly.
• Maintain a healthy weight: Obesity is associated with higher inflammatory cytokine levels and increased RA risk. Weight loss reduces systemic inflammation.
• Eat an anti-inflammatory diet: The Mediterranean diet - rich in omega-3 fatty acids (oily fish), olive oil, fruits, vegetables, and nuts - has been associated with reduced RA risk and symptom improvement in existing RA.
• Exercise regularly: Moderate physical activity (walking, swimming, cycling) reduces inflammation and helps maintain joint mobility. It does not accelerate joint damage in RA.
• Omega-3 supplementation: Fish oil supplements (providing at least 2.7 g/day of EPA and DHA combined) have been shown to reduce joint stiffness and pain in RA patients.
• Limit alcohol: While moderate alcohol consumption has been associated with reduced RA risk in some epidemiological studies, heavy drinking increases systemic inflammation.

Medical management (if RA is diagnosed)

• Disease-modifying anti-rheumatic drugs (DMARDs): Methotrexate is the first-line treatment. If insufficient, hydroxychloroquine, sulfasalazine, or leflunomide may be added.
• Biologic therapies: TNF inhibitors (adalimumab, etanercept), IL-6 inhibitors (tocilizumab), and B-cell depleting agents (rituximab) are used for moderate-to-severe RA.
• JAK inhibitors: Newer oral therapies such as baricitinib and tofacitinib offer alternatives to biologics.
• Early aggressive treatment: The "treat-to-target" strategy aims for clinical remission or low disease activity. Starting treatment within 3 months of symptom onset dramatically improves long-term outcomes.

When Should You Get Tested?

Consider anti-CCP testing if you experience:

• Joint pain, swelling, or stiffness lasting more than 6 weeks - particularly in the small joints of the hands, wrists, or feet
• Morning stiffness lasting more than 30 minutes
• Symmetrical joint involvement (both hands, both wrists, etc.)
• A family history of rheumatoid arthritis (first-degree relatives have a 3–5 fold increased risk)
• Elevated ESR or CRP with unexplained joint symptoms
• Positive rheumatoid factor - anti-CCP adds specificity to the diagnosis
• Fatigue, weight loss, or general malaise alongside joint symptoms

Anti-CCP is not typically part of routine health screening for asymptomatic individuals. However, if you have a strong family history of RA and are concerned about your risk, testing is reasonable - particularly as early intervention can prevent joint damage.

Which Lola Health Tests Include Anti-CCP?

Anti-CCP is available in Lola Health's more comprehensive panels designed for advanced health assessment:

• Peak Insights (70 Biomarkers) — Our most comprehensive panel, including autoimmune and inflammatory markers alongside metabolic, hormonal, and nutritional assessments.

If you are specifically concerned about joint symptoms or autoimmune disease, we recommend discussing your results with a GP or rheumatologist, particularly if your anti-CCP level is positive.

All Lola Health tests use a venous blood draw at one of our nationwide partner clinics. Results are reviewed by a doctor and returned within 4 working days.